Teva (TEVA) Hits Multi-Year High as Q3 Strengthens FY25 Profitability Expectations

Core Insights - Teva Pharmaceutical Industries Ltd. has shown significant stock performance, reaching a multi-year high and closing up by 20.23% at $24.60 after intra-day trading peaked at $25, driven by strong Q3 results that bolster expectations for a profitable full-year 2025 [1][3]. Financial Performance - The company reported a net income of $460 million in Q3, a remarkable 211% improvement compared to a net loss of $390 million in the same quarter last year [2]. - Revenues increased by 3.4% year-on-year, reaching $4.48 billion, up from $4.33 billion, supported by strong sales growth in its brands: Austedo (up 38%), Ajovy (up 19%), and Uzedy (up 24%) [3]. Revenue Outlook - Teva has adjusted its revenue growth outlook, lowering the upper range to $17 billion from $17.2 billion, while maintaining the lower end at $16.8 billion [4]. - The company expects adjusted EBITDA to be between $4.8 billion and $5 billion, which is an increase from the previous lower end of $4.7 billion [4].